Changes in Donor‐Derived Cell‐Free DNA Before and After Rejection and De Novo DSA Detection in Primary and Repeat Kidney Transplant Recipients
Clinical Transplantation · 2024-11 · 38 (11)
DOI: 10.1111/ctr.70019 ↗At a glance
Journal article in Clinical Transplantation, 2024-11. Written by Sandesh Parajuli and 7 co-authors. Institution: Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Major MEDLINE topics: Kidney Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Isoantibodies. Cited 6 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: CareDx.
Abstract (original language)
Background
Serial monitoring of dd‐cfDNA and change from baseline can provide meaningful information beyond absolute thresholds. We describe dd‐cfDNA trajectories from the baseline before and after acute rejection (AR) and de novo donor‐specific antibodies (dnDSA) detection in kidney transplant recipients (KTRs).
Methods
We included KTR from 02/2019 to 03/2022 with serial dd‐cfDNA. The primary analysis compared the time‐varying change in dd‐cfDNA from baseline in KTR first AR on biopsy [AR] to patients with no‐AR on biopsy [no‐AR].
Results
151 KTR were analyzed (AR = 56 KTR, no‐AR = 95 KTRs). In the AR group, dd‐cfDNA rose ahead of diagnosis: median rise from baseline was 75% at −3 months, 32% at −2 months, and 325% at −1 month before biopsy. At the time of biopsy, the median rise in dd‐cfDNA from baseline was 291% (IQR [interquartile range] 88%–1081%) in AR and 17% (IQR 0%– 194%) in no‐AR ( p < 0.0001). Following treatment, dd‐cfDNA values fell in the AR group with a median change from baseline of 94.7% at +1 month, 10.5% at +2 months, and 0% at +3 months. These trajectories were not observed in the no‐AR group. Similarly, there were no significant differences in eGFR (estimated glomerular filtration rate) trajectories between the two groups. The median change from baseline to dnDSA detection was 141% (IQR 112%–574%). In KTRs with persistent rejection, median dd‐cfDNA was 0.95% (IQR 0.44–1.8) compared to 0.19% (IQR 0.12–0.31) in subjects with no rejection on follow‐up ( p < 0.001).
Conclusion
The significant changes from baseline observed before and after AR show how serial monitoring enhances dd‐cfDNA utility and allows for earlier identification of evolving injury and monitoring treatment response.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- CareDx, Inc, Brisbane, California, USA.
ORCID profiles: Sandesh Parajuli, Neetika Garg, Didier Mandelbrot
Funding
- CareDx
Cite
APA
Parajuli, S., Garg, N., Dodin, B., Breyer, I., Zona, E., Patel, S., Pinney, K., & Mandelbrot, D. (2024). Changes in Donor‐Derived Cell‐Free DNA Before and After Rejection and De Novo DSA Detection in Primary and Repeat Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70019
Vancouver
Parajuli S, Garg N, Dodin B, Breyer I, Zona E, Patel S, et al. Changes in Donor‐Derived Cell‐Free DNA Before and After Rejection and De Novo DSA Detection in Primary and Repeat Kidney Transplant Recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.70019
BibTeX
@article{Parajuli2024,
author = {Parajuli, Sandesh and Garg, Neetika and Dodin, Ban and Breyer, Isabel and Zona, Emily and Patel, Shree and Pinney, Kevin and Mandelbrot, Didier},
title = {Changes in Donor‐Derived Cell‐Free DNA Before and After Rejection and De Novo DSA Detection in Primary and Repeat Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.70019}
}
EUVIMED